Skip to main content
Premium Trial:

Request an Annual Quote

ImmusanT Nabs $12M Investment to Support Celiac Disease CDx and Immunotherapy

NEW YORK (GenomeWeb) – ImmusanT today announced it has raised $12 million in Series B financing from Vatera Healthcare Partners to continue developing Nexvax2, an immunotherapy for celiac disease, as well as a companion diagnostic to pair with the treatment and a standalone blood-based diagnostic.

The Cambridge, Mass.-based firm will continue to develop its whole-blood functional T-cell test as both a companion diagnostic to identify patients most likely to respond to Nexvax2 and as a standalone test.

Nexvax2 is an adjuvant-free, disease-modifying immunotherapy for celiac disease that reprograms a patient's immune system to tolerate gluten in the diet. It is comprised solely of three gluten-derived peptides in saline that are responsible for the immune reaction that causes celiac disease. ImmusanT recently completed two Phase 1b studies to demonstrate safety, tolerability, and bioactivity of Nexvax2, and Phase II trials will begin in early 2015, the firm said in a statement.

The funding follows $20 million that ImmusanT received from Vatera in 2011 for the development of celiac diagnostic tools.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.